Evaluation of the effects of clarithromycin on renal toxicity of cisplatin in male mice

Abstract

Introduction: One major adverse effect of cisplatin that restricts its use in cancer patients is nephrotoxicity. Reducing cisplatin nephrotoxicity, the primary adverse effect of this medication, is therefore crucial. This work is significant because clarithromycin can stop the generation of proinflammatory factors that are created in the cisplatin toxicity pathway.Aim: Analyzing how clarithromycin affects male mice's renal damage from cisplatin.Methods: Five groups of 10 male mice weighing 20-30 g received the following drug regimens for 9 days: Group 1: Control solution with a dose of DMSO 10 ml/kg, SC + Saline 10 ml/kg, IP. Group 2: Control solution with a dose of DMSO 10 ml/kg, SC. Group 3: Clarithromycin solution 25 mg/kg/day, SC. Group 4: Clarithromycin solution 50 mg/kg/day, SC. Group 5: Clarithromycin solution 100 mg/kg/day, SC. Then, on the 6th day, a single dose of 20 mg/kg of cisplatin was injected IP into groups 2 to 5. After 3 days, the animals underwent surgery with ketamine and xylazine and were evaluated for serum urea and creatinine levels and histopathology of kidney tissue.Results: Receiving different doses of clarithromycin was effective in preventing acute kidney injury caused by cisplatin, and part of this effect may be related to the inhibitory effects of a transcription factor called NF-κB. It is also possible that clarithromycin prevented cisplatin-induced acute kidney injury by inhibiting intracellular oxidative stress pathways.Conclusion: In fact, when mice received clarithromycin, the amount of kidney tissue damage in mice receiving cisplatin was significantly reduced.